Compagnie Lombard Odier SCmA Sells 18,576 Shares of Thermo Fisher Scientific Inc. (NYSE:TMO)

Compagnie Lombard Odier SCmA lessened its stake in shares of Thermo Fisher Scientific Inc. (NYSE:TMO) by 8.7% during the fourth quarter, according to the company in its most recent disclosure with the SEC. The fund owned 193,896 shares of the medical research company’s stock after selling 18,576 shares during the quarter. Thermo Fisher Scientific makes up 1.5% of Compagnie Lombard Odier SCmA’s holdings, making the stock its 15th biggest holding. Compagnie Lombard Odier SCmA owned approximately 0.05% of Thermo Fisher Scientific worth $100,871,000 as of its most recent filing with the SEC.

A number of other hedge funds and other institutional investors have also recently modified their holdings of the stock. AMF Tjanstepension AB bought a new stake in shares of Thermo Fisher Scientific in the third quarter worth $42,409,000. Exchange Traded Concepts LLC grew its stake in shares of Thermo Fisher Scientific by 8.0% in the third quarter. Exchange Traded Concepts LLC now owns 2,137 shares of the medical research company’s stock worth $1,322,000 after purchasing an additional 159 shares during the last quarter. Creative Planning grew its stake in shares of Thermo Fisher Scientific by 3.1% in the third quarter. Creative Planning now owns 101,174 shares of the medical research company’s stock worth $62,583,000 after purchasing an additional 3,072 shares during the last quarter. IQ EQ FUND MANAGEMENT IRELAND Ltd grew its stake in shares of Thermo Fisher Scientific by 15.5% in the third quarter. IQ EQ FUND MANAGEMENT IRELAND Ltd now owns 3,209 shares of the medical research company’s stock worth $1,985,000 after purchasing an additional 431 shares during the last quarter. Finally, BOS Asset Management LLC bought a new stake in shares of Thermo Fisher Scientific in the third quarter worth $204,000. Institutional investors own 89.23% of the company’s stock.

Wall Street Analyst Weigh In

Several equities analysts recently issued reports on the stock. Wells Fargo & Company boosted their target price on shares of Thermo Fisher Scientific from $660.00 to $680.00 and gave the company an “overweight” rating in a report on Friday, January 31st. Robert W. Baird dropped their target price on shares of Thermo Fisher Scientific from $632.00 to $622.00 and set an “outperform” rating on the stock in a report on Thursday, October 24th. Sanford C. Bernstein upgraded shares of Thermo Fisher Scientific from a “market perform” rating to an “outperform” rating and set a $630.00 target price on the stock in a report on Friday, January 10th. Bernstein Bank boosted their target price on shares of Thermo Fisher Scientific from $565.00 to $625.00 and gave the company a “market perform” rating in a report on Tuesday, October 22nd. Finally, Raymond James restated an “outperform” rating and issued a $667.00 target price (up previously from $650.00) on shares of Thermo Fisher Scientific in a report on Monday, February 3rd. Four investment analysts have rated the stock with a hold rating and nineteen have issued a buy rating to the company. According to MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and an average target price of $658.00.

Insiders Place Their Bets

In other Thermo Fisher Scientific news, EVP Gianluca Pettiti sold 300 shares of the company’s stock in a transaction dated Tuesday, February 4th. The shares were sold at an average price of $585.59, for a total value of $175,677.00. Following the completion of the sale, the executive vice president now directly owns 16,363 shares of the company’s stock, valued at approximately $9,582,009.17. This represents a 1.80 % decrease in their position. The sale was disclosed in a document filed with the SEC, which is accessible through the SEC website. Also, CFO Stephen Williamson sold 9,825 shares of the stock in a transaction that occurred on Tuesday, February 4th. The shares were sold at an average price of $585.59, for a total transaction of $5,753,421.75. Following the transaction, the chief financial officer now directly owns 27,296 shares of the company’s stock, valued at $15,984,264.64. This represents a 26.47 % decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last ninety days, insiders sold 20,125 shares of company stock valued at $11,231,699. Corporate insiders own 0.34% of the company’s stock.

Thermo Fisher Scientific Trading Down 1.0 %

TMO opened at $532.63 on Friday. The company has a debt-to-equity ratio of 0.59, a current ratio of 1.66 and a quick ratio of 1.29. Thermo Fisher Scientific Inc. has a fifty-two week low of $493.30 and a fifty-two week high of $627.88. The firm has a market capitalization of $203.73 billion, a PE ratio of 32.22, a P/E/G ratio of 3.18 and a beta of 0.77. The company’s 50-day moving average is $548.21 and its 200 day moving average is $571.28.

Thermo Fisher Scientific (NYSE:TMO) last issued its quarterly earnings data on Thursday, January 30th. The medical research company reported $6.10 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $5.94 by $0.16. Thermo Fisher Scientific had a net margin of 14.78% and a return on equity of 17.51%. As a group, research analysts predict that Thermo Fisher Scientific Inc. will post 23.28 earnings per share for the current fiscal year.

Thermo Fisher Scientific declared that its board has authorized a share buyback plan on Friday, November 15th that authorizes the company to buyback $4.00 billion in shares. This buyback authorization authorizes the medical research company to repurchase up to 2% of its shares through open market purchases. Shares buyback plans are often a sign that the company’s leadership believes its shares are undervalued.

About Thermo Fisher Scientific

Thermo Fisher Scientific Inc provides life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and biopharma services in the North America, Europe, Asia-Pacific, and internationally. The company's Life Sciences Solutions segment offers reagents, instruments, and consumables for biological and medical research, discovery, and production of drugs and vaccines, as well as diagnosis of infections and diseases; and solutions include biosciences, genetic sciences, and bio production to pharmaceutical, biotechnology, agricultural, clinical, healthcare, academic, and government markets.